Auspex Pharmaceuticals Company Profile (NASDAQ:ASPX)

About Auspex Pharmaceuticals (NASDAQ:ASPX)

Auspex Pharmaceuticals logoAuspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ASPX
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $94.00
  • 200 Day Moving Avg: $59.00
  • 52 Week Range: $15.00 - $101.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -50.50
  • P/E Growth: 0
Profitability:
  • Return on Equity: -61.66%
  • Return on Assets: -50.55%
Misc:
  • Average Volume: 634,233 shs.
 

Frequently Asked Questions for Auspex Pharmaceuticals (NASDAQ:ASPX)

What is Auspex Pharmaceuticals' stock symbol?

Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."

How were Auspex Pharmaceuticals' earnings last quarter?

Auspex Pharmaceuticals Inc (NASDAQ:ASPX) announced its quarterly earnings results on Monday, March, 16th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.15. View Auspex Pharmaceuticals' Earnings History.

Who are some of Auspex Pharmaceuticals' key competitors?

How do I buy Auspex Pharmaceuticals stock?

Shares of Auspex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auspex Pharmaceuticals' stock price today?

One share of Auspex Pharmaceuticals stock can currently be purchased for approximately $101.00.


MarketBeat Community Rating for Auspex Pharmaceuticals (NASDAQ ASPX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Auspex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Auspex Pharmaceuticals (NASDAQ:ASPX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
Earnings by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
Earnings History by Quarter for Auspex Pharmaceuticals (NASDAQ ASPX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2015Q4 2014($0.59)($0.74)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.45)($0.73)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.40)($0.45)ViewN/AView Earnings Details
5/13/2014Q114($0.47)($0.52)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Auspex Pharmaceuticals (NASDAQ:ASPX)
Current Year EPS Consensus Estimate: $-4 EPS
Next Year EPS Consensus Estimate: $-2 EPS

Dividends

Dividend History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Auspex Pharmaceuticals (NASDAQ:ASPX)
Insider Trades by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
Insider Trades by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2015David A StamlerInsiderSell3,000$80.00$240,000.00View SEC Filing  
2/13/2015Ventures Vii Lp CmeaMajor ShareholderSell122,667$63.08$7,737,834.36View SEC Filing  
2/11/2015Ventures Vii Lp CmeaMajor ShareholderSell84,154$61.06$5,138,443.24View SEC Filing  
2/6/2015Ventures Vii Lp CmeaMajor ShareholderSell93,179$59.39$5,533,900.81View SEC Filing  
1/28/2015Alex ZissonDirectorSell730,000$53.11$38,770,300.00View SEC Filing  
1/28/2015James E FlynnInsiderBuy1,500,000$56.50$84,750,000.00View SEC Filing  
1/28/2015Panorama Capital, L.P.Major ShareholderSell270,000$53.11$14,339,700.00View SEC Filing  
12/22/2014David A StamlerInsiderSell2,660$53.55$142,443.00View SEC Filing  
12/18/2014Ventures Vii Lp CmeaMajor ShareholderSell195,000$50.14$9,777,300.00View SEC Filing  
10/30/2014Ventures Vii Lp CmeaMajor ShareholderSell19,000$27.15$515,850.00View SEC Filing  
10/28/2014Ventures Vii Lp CmeaMajor ShareholderSell14,500$27.02$391,790.00View SEC Filing  
10/27/2014Ventures Vii Lp CmeaMajor ShareholderSell3,413$27.11$92,526.43View SEC Filing  
10/24/2014Ventures Vii Lp CmeaMajor ShareholderSell16,500$26.97$445,005.00View SEC Filing  
10/6/2014Ventures Vii Lp CmeaMajor ShareholderSell7,109$23.45$166,706.05View SEC Filing  
9/19/2014Gerald T ProehlDirectorBuy1,466$21.75$31,885.50View SEC Filing  
9/5/2014Ventures Vii Lp CmeaMajor ShareholderSell25,600$23.86$610,816.00View SEC Filing  
9/3/2014Ventures Vii Lp CmeaMajor ShareholderSell22,700$23.08$523,916.00View SEC Filing  
8/28/2014Ventures Vii Lp CmeaMajor ShareholderSell29,600$22.03$652,088.00View SEC Filing  
8/26/2014Ventures Vii Lp CmeaMajor ShareholderSell6,300$21.35$134,505.00View SEC Filing  
8/22/2014Ventures Vii Lp CmeaMajor ShareholderSell1,700$20.56$34,952.00View SEC Filing  
7/16/2014R Scott GreerDirectorBuy5,190$19.25$99,907.50View SEC Filing  
2/10/2014James E FlynnInsiderBuy700,000$12.00$8,400,000.00View SEC Filing  
2/10/2014Panorama Capital, L.P.Major ShareholderBuy333,334$12.00$4,000,008.00View SEC Filing  
2/10/2014Pratik ShahCEOBuy8,333$12.00$99,996.00View SEC Filing  
2/10/2014Sepehr SarsharDirectorBuy67,263$12.00$807,156.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Auspex Pharmaceuticals (NASDAQ:ASPX)
Latest Headlines for Auspex Pharmaceuticals (NASDAQ:ASPX)
Source:
DateHeadline
rttnews.com logoSanofi Genzyme Reports Results From Phase 2 Open-Label Extension Study
www.rttnews.com - July 10 at 4:07 PM
finance.yahoo.com logoAvexis Inc. (AVXS): RA Capital Management Ups Its Stake
finance.yahoo.com - April 13 at 8:52 PM
finance.yahoo.com logoChardan Analyst Suggests An AveXis-Ionis Pair Trade
finance.yahoo.com - February 6 at 3:43 PM
thestreet.com logoHurry! These 5 Stocks Are About to Break Out Explosively
www.thestreet.com - January 13 at 4:10 PM
finance.yahoo.com logoCitron Research On AveXis: This Will Be One Of 2017's Biotech Blowups
finance.yahoo.com - December 15 at 3:28 PM
morningstar.co.uk logoPharma, Biotech Shares Down After Trump Pledge To Cut Drug Prices
www.morningstar.co.uk - December 8 at 3:55 PM
investopedia.com logoAll Eyes on These Two Biotech Firms Ahead of FDA Decisions (VCEL, SGYP)
www.investopedia.com - December 8 at 3:55 PM
finance.yahoo.com logoShould You Sell AveXis (AVXS) Before Earnings?
finance.yahoo.com - November 9 at 12:31 PM
finance.yahoo.com logoCan The Uptrend Continue for AveXis (AVXS)?
finance.yahoo.com - November 4 at 2:00 PM
fool.com logoHere's Why AveXis Shot Up 24.5% Today
www.fool.com - November 2 at 3:58 PM
marketwatch.com logoIf you want to know which way the market is heading, follow the leaders
www.marketwatch.com - October 17 at 3:35 PM
finance.yahoo.com logoAveXis (AVXS) Shows Strength: Stock Adds 6.3% in Session
finance.yahoo.com - September 20 at 9:32 AM
finance.yahoo.com logoWhy AveXis (AVXS) Might Surprise This Earnings Season
finance.yahoo.com - August 9 at 12:26 PM
finance.yahoo.com logoRon Baron's Top New Stock Holdings
finance.yahoo.com - May 31 at 11:15 PM
finance.yahoo.com logoWhy Teva’s Specialty Medicines Performance Declined in 1Q15
finance.yahoo.com - May 8 at 11:07 PM
biz.yahoo.com logoAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquis
biz.yahoo.com - May 5 at 4:50 PM
finance.yahoo.com logoTeva 1Q15 Earnings Preview: Stock Up 10.3% since Last Quarter
finance.yahoo.com - April 29 at 3:06 AM
finance.yahoo.com logoTeva Earnings Preview: Auspex Acquisition to Support Growth
finance.yahoo.com - April 28 at 9:06 PM
finance.yahoo.com logoMylan rejects Teva's $40.1 billion buyout offer
finance.yahoo.com - April 27 at 11:35 AM
finance.yahoo.com logoInvesting in IPOs: Why Investors Should Proceed with Caution
finance.yahoo.com - April 20 at 8:02 AM
biz.yahoo.com logoAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - April 17 at 9:02 AM
finance.yahoo.com logoThe Bull Case: Supply & Demand Edition
finance.yahoo.com - March 31 at 10:14 AM
finance.yahoo.com logoGLOBAL MARKETS-Stocks rally on merger activity; dollar gains
finance.yahoo.com - March 30 at 4:38 PM

Social

Chart

Auspex Pharmaceuticals (ASPX) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff